Fate Therapeutics to Present at Upcoming September Investor Conferences
31 8월 2023 - 9:00PM
Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”)
(NASDAQ: FATE), a clinical-stage biopharmaceutical company
dedicated to bringing a first-in-class pipeline of induced
pluripotent stem cell (iPSC)-derived cellular immunotherapies to
patients with cancer and autoimmune disorders, today announced that
the Company will participate in the following upcoming investor
conferences:
Citi’s 18th Annual BioPharma Conference on Thursday, September
7, 2023 in Boston, Massachusetts
- Hosting 1x1 investor meetings
only
Wells Fargo 2023 Healthcare Conference on Friday, September 8,
2023 at 9:30 AM ET in Boston, Massachusetts
- Participating in a fireside chat and hosting 1x1 investor
meetings
A live webcast, if recorded, of each presentation can be
accessed under “Events & Presentations” in the Investors
section of the Company’s website at www.fatetherapeutics.com. The
archived webcast will be available on the Company’s website shortly
after the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company
dedicated to bringing a first-in-class pipeline of induced
pluripotent stem cell (iPSC)-derived cellular immunotherapies to
patients with cancer and autoimmune disorders. Using its
proprietary iPSC product platform, the Company has established a
leadership position in creating multiplexed-engineered iPSC lines
and in the manufacture and clinical development of off-the-shelf,
iPSC-derived cell products. The Company’s effector cell pipeline
includes multiplexed-engineered, iPSC-derived natural killer (NK)
cell and T-cell product candidates, which incorporate novel
synthetic controls of cell function, such as chimeric antigen
receptors (CARs) to target tumor-associated antigens, and are
intended to deliver multiple mechanisms of therapeutic importance
to patients including in combination with well-established cancer
therapies. Fate Therapeutics is headquartered in San Diego, CA. For
more information, please visit www.fatetherapeutics.com.
Contact:Christina TartagliaStern Investor
Relations, Inc.212.362.1200christina.tartaglia@sternir.com
Fate Therapeutics (NASDAQ:FATE)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Fate Therapeutics (NASDAQ:FATE)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024